Inmune Bio, Inc. (INMB): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$23.62M

Year ended 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$23.62M	n/a	2026-03-30, From 2025-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Inmune Bio, Inc. (INMB)	2025-12-31	-$23.62M	n/a
Entera Bio Ltd. (ENTX)	2025-12-31	-$7.48M	n/m
AIM ImmunoTech Inc. (AIM)	2024-12-31	-$14.91M	n/a
Senti Biosciences Holdings, Inc. (SNTI)	2025-12-31	-$43.64M	n/m
VivoSim Labs, Inc. (VIVS)	2026-03-31	-$10.83M	n/m
aTYR PHARMA INC (ATYR)	2025-12-31	-$62.06M	n/m
Cardiff Oncology, Inc. (CRDF)	2025-12-31	-$37.97M	n/m
Prokidney Corp. (PROK)	2025-12-31	-$135.31M	n/m
Pluri Inc. (PLUR)	2026-06-30	-$20.22M	n/m

Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗